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Abstract 
Several case reports suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may be 
associated with thrombotic microangiopathy (TMA). We conducted a matched case-control 
study with linked administrative healthcare data in Ontario, Canada to assess the relationship 
between TMA hospitalization and recent exposure to prescription NSAIDs versus 
acetaminophen (where the latter was a referent group with no known association with TMA). 
Cases and controls were drawn from a source population of adults who filled a prescription 
for NSAIDs or acetaminophen between 1996 and 2015 (restricted to adults with prescription 
drug benefits). Cases comprised individuals hospitalized with TMA between 1996 and 2015. 
Controls were matched to cases (4:1) on demographic and medical risk factors. Cases (n=38) 
were less likely to have received a recent prescription for NSAIDs relative to acetaminophen 
(adjusted odds ratio 0.37, 95% confidence interval 0.16-0.84). Results were similar in two 
additional analyses with alternative referent groups. Overall, the results of this study do not 
support a harmful association between NSAID use and TMA. 
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Chapter 1  
1 Introduction 
 
Non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used analgesic and anti-
inflammatory agents, and one of the most widely used classes of drugs in the world.1,2 
Many studies have investigated associations between NSAID use and a wide variety of 
adverse medical reactions. Up to 25% of all reported adverse drug events may be 
associated with NSAID use, and the risk of adverse drug events increases with age.3  
Thrombotic microangiopathy (TMA) describes a rare hematological disorder 
characterized by thrombocytopenia (a low concentration of blood platelets) and 
microangiopathic hemolytic anemia (a low concentration of red blood cells due to a 
rupture of those cells). Several major organ systems can be damaged by TMA, including 
the central nervous, cardiovascular and renal systems.4–6 Identifying drugs associated 
with TMA development is a relatively novel area of research. Its existence is justified by 
the clinical severity of the disease, the abundance of drugs that could be culprits in drug-
induced TMA, the high frequency of exposure to these drugs, and the lack of 
understanding of drug-induced TMA etiology and pathogenesis.7 While NSAIDs have 
been linked with TMA in several case reports, this potential association has yet to be 
investigated in analytic studies.8–13 Therefore, we conducted a matched case-control study 
to assess whether a case of TMA was more likely to be associated with a prior 
prescription of NSAID compared to a referent prior prescription of acetaminophen. The 
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study sample consisted of Ontario residents who had a prescription NSAID or 
acetaminophen dispensed at an outpatient pharmacy between 1991 and 2015. 
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Chapter 2  
2 Background and Literature Review 
2.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs used for a variety 
of symptoms such as pain, fever, rheumatic, and inflammatory disorders.14–16 NSAIDs 
work by inhibiting prostaglandin synthesis.17 Prostaglandins are lipid biological factors 
that behave similarly to hormones and carry out a great number of functions (including 
inflammation onset) when interacting with specific prostaglandin receptors native to 
different cell types.17 Prostaglandins are derived from arachidonic acid through the action 
of cyclooxygenase (COX) enzymes, classified as COX-1 or COX-2. The resulting 
inflammation and pain alleviation is a product of terminating prostaglandin synthesis by 
cyclooxygenase (COX) enzymes.14–17 Certain NSAIDs will non-selectively inhibit both 
COX-1 and COX-2 enzymes, while the goal of contemporary NSAIDs seem to be 
selective COX-2 inhibition. COX-2 is believed to be the root of inflammation and pain 
response while sidestepping COX-1 may mitigate unnecessary adverse gastrointestinal 
outcomes.14,15,18 
NSAIDs are undisputedly among the most widely used medications in the world, with 
over 30 million users daily.1,2 The adverse outcomes have the potential to affect most, if 
not all, major physiological systems in the human body, including cardiovascular, 
gastrointestinal, and renal systems.2,19 NSAIDs are relatively inexpensive drugs on the 
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market to both manufacturers and consumers. However, adverse events associated with 
this class of drugs can be costly to the healthcare system.2,15 Studies in the United States 
indicate gastrointestinal complications from NSAID use have caused over 100,000 
hospitalizations, over 16,000 deaths, and over $500 million in healthcare costs.20 
 
2.2 Thrombotic microangiopathy (TMA) 
Thrombotic microangiopathy (TMA) has several causes and is a clinical state 
characterized by thrombocytopenia and microangiopathic hemolytic anemia and may also 
be associated with acute kidney injury, fever, and acute neurological symptoms. TMA is 
further classified as Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic 
Uremic Syndrome (HUS), which share many similar clinical symptoms but can differ in 
their risk factors.4–6  
 
2.2.1 Thrombotic thrombocytopenic purpura (TTP) 
Thrombotic thrombocytopenic purpura (TTP) is a relatively severe form of TMA, with a 
mortality rate of up to 90% unless promptly treated with plasma exchange (PLEX).4,21,22 
The pathology of TTP can be attributed to deficiency in ADAMTS13 (A Disintegrin And 
Metalloprotease with a ThromboSpondin type 1 motif, member 13) protease, which 
cleaves von Willebrand factor into short multimers. Low ADAMTS13 activity 
perpetuates the presence of long multimers of von Willebrand factor, which can cause 
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platelets to aggregate and form clots in the small blood vessels of the body.6,21,22 As a 
consequence, the features of TTP include thrombocytopenia (a consumption of platelets), 
neurological disorders (confusion, impaired vision, encephalopathy, coma), fever, 
jaundice, acute kidney injury, and heart failure. A diagnosis of TTP is supported by 
evidence of a severe deficiency of ADAMTS13 activity (<5%) and the presence of IgG 
antibody inhibitors.21,23–26  
The estimated incidence of TTP is 2 to 11 cases per 1,000,000 persons each year.21,22,27 
The reasons for TTP may be congenital, acquired, or idiopathic. Congenital and acquired 
forms of TTP most often relate to ADAMTS13 deficiency.22 There are also instances 
where there is no recognized cause for the TTP making it idiopathic.21,22,27,28 
Biologically, in most cases of TTP there is antibody inhibition of ADAMTS13 29,30 The 
root cause of inhibitory antibodies to ADAMTS13 is not well understood. Other factors 
implicated in the pathogenesis of TMA include exposure to shiga-toxin, endothelial 
dysfunction, and drug-mediated events.31,32 
 
2.2.2 Hemolytic uremic syndrome (HUS) 
Hemolytic uremic syndrome (HUS) shares many clinical manifestations with TTP, but 
the focus is placed on acute kidney injury (which when most severe requires treatment 
with dialysis) and pathological infection by diarrhea-positive toxin producing bacteria 
(shiga-toxin and verocytoxin). A small portion of patients (roughly 10%) do not present 
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with diarrhea (diarrhea-negative) prior to TMA-associated symptoms, who have a worse 
prognosis than others who present with diarrhea.33,34 
Diarrhea-positive HUS occurs most commonly in children, specifically those below the 
age of 5 years. Various sources report an annual incidence of 0.2-3.4 cases per 100,000 
persons per year in Germany, up to 8 cases per 100,000 persons per year in North 
America, and 1.4-3.1 cases per 100,000 persons per year in Canada.6,21,33,35–37 
 
2.3 Treatment of TMA disorders 
Plasma exchange (PLEX) is a therapy that dramatically improves survival in TTP; for 
this reason there is a low threshold to start PLEX when TTP is suspected.21,38 It is 
common for patients to receive multiple rounds of PLEX over several days before disease 
remission. Relapse, defined as reoccurrence of TTP more than 30 days from the previous 
episode, is observed in 20%-50% of patients.21,26,34,39–41 It is important to identify risk 
factors and the root cause of TMA to effectively prevent and manage relapses.  
Along with dialysis, PLEX may also be used in the treatment of HUS. Furthermore, 
evidence from some studies supports the use of rituximab as treatment in immune-
mediated TTP. 21,33,42,43 Other treatment options include aspirin, dipyridamol, or 
glucocorticoids; however, patient outcomes do not seem to differ statistically or clinically 
with the inclusion of these drugs in the treatment regime.44,45 
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2.4 Long-term outcomes of TMA 
Short-term outcomes of TMA have substantially improved with the use of PLEX therapy. 
Several important complications persist beyond the 6 months following TMA. First and 
foremost, TMA can relapse, at a rate that varies between 8%-84%, and seems to increase 
with increasing length of follow-up.46,47 Roughly 10% of all deaths in the 3 years 
following TMA have been attributed to a TMA relapse.32,48 Other long-term outcomes 
after TMA treated with plasma exchange include chronic kidney disease, hypertension, 
stroke, depression, preeclampsia, reduced neurocognitive function, and reduced health-
related quality of life (indicated by lower physical component summary scores and/or 
mental component summary scores).46,47,49–52 
 
2.5 Drug-induced TMA 
Adverse drug events are well recognized as a potential cause of TMA.7,53 Drug-induced 
thrombotic microangiopathy (DITMA) is formed under two major mechanisms. Immune-
related DITMA occurs when the drug prompts the generation of antibodies that interacts 
with cells, eventually leading to TMA associated symptoms such as platelet 
aggregation.54,55 Toxic-related DITMA is often dependent on drug dose. This type of 
DITMA may develop from tissue injury as a direct consequence of patients ingesting 
large quantities of a drug over a short period of time.56 
DITMA occurs in both children and adults. Analyses of the Oklahoma Thrombotic 
Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) registry suggest 
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5% of all TMA cases are due to drugs. However, the true incidence of DITMA is difficult 
to ascertain due to overlap with other prominent risk factors, the absence of appropriate 
diagnostic tools, and lack of understanding of pathological mechanisms.7,53 
 
2.6 Drugs associated with TMA 
In a systematic review of published DITMA case reports, 78 drugs were identified as a 
potential cause of TMA. However, the evidence only qualitatively supports 22 (28%) of 
these claims.7 Drugs most commonly associated with TMA are those indicated for 
malaria (Quinine), cancer (gemcitabine, bevacizumab, mitomycin, oxaliplatin, 
pentostatin, sunitinib), immunosuppression (cyclosporine, sirolimus, tacrolimus), 
antibiotics (trimethoprim-sulfamethoxazole), and drugs of abuse (cocaine, ecstasy, 
oxymorphone).7,53 
 
2.7 Risk factors for TMA 
TMA occurs more commonly in women than men.57–59 It is unclear as to why women 
have a higher risk of TMA, but studies with non-selective samples often show higher 
proportions of women with TMA as opposed to men.57,60,61  
Malignant hypertension potentially affects TMA on two fronts: first, reduced 
ADAMTS13 activity has been observed in malignant hypertension, and second, 
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endothelium damage due to malignant hypertension may trigger release of von 
Willebrand factors.62–64  
TMA is often induced in various late-stage cancers, such as prostate, breast, lung, and 
ovarian cancers. The pathophysiology of cancer-induced TMA is not well understood, 
but many similar clinical symptoms are present in both TMA and cancer, most commonly 
microangiopathic hemolytic anemia.65–68  
Antibodies to ADAMTS13 may form in patients with recent transplants and in patients 
diagnosed with auto-immune diseases (e.g. systemic lupus erythematosus, HIV). As 
previously discussed, the underlying pathophysiology of TMA is not well understood.69–
73  
Fakhouri et al. found a considerable risk for TMA during pregnancy in a review 
published in 2010.74 The incidence of HUS is estimated to be 1 in 25,000 pregnancies, 
slightly higher than the general population. However, very little is known about the 
pathophysiology of pregnancy related TMA, 74,75 
 
2.7.1 Shiga toxin-producing Escherichia coli infection 
Shiga toxin-producing Escherichia coli (STEC) infections are characterized by the 
presence of at least one phage-encoded Shiga toxin gene (stx1 or stx2). STEC infections 
are associated with an array of diseases, ranging from mild gastrointestinal disturbances 
to clinically severe conditions, including HUS.76 A large proportion of patients with 
critical STEC infections also develop conditions commonly associated with infection 
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such as sepsis including septic shock.77 An English study by Byrne et al. documented 
3,717 suspected cases of STEC infection between 2009 and 2012. 3,267 (90.7%) cases of 
infection were confirmed and 215 (6.4%) cases progressed to HUS. The HUS cases were 
predominately women and children, and the highest proportion of HUS cases occurred in 
females under the age of 14.78 Rural residents were more likely to be infected; the 
incidence of STEC infections was roughly 4 fold higher in individuals residing in rural 
areas compared to urban residents.78 
 
2.8 NSAID indications and characteristics of NSAID users 
The main indications for NSAIDs are pain, inflammation, and associated diseases of an 
acute and chronic nature. For example, NSAIDs are commonly prescribed for patients 
suffering from arthritic conditions (e.g. osteoarthritis, rheumatoid arthritis) and other 
autoimmune diseases.14,15,79 
Older adults are the most frequent NSAIDs users. A meta-analysis of 16 studies by 
Gabriel et al. found that roughly 40% of NSAID prescriptions were for patients over the 
age of 60.80  
The Alabama NSAID Patient Safety Study administered surveys to understand patterns 
of NSAID use prescribed by 48 participating primary care physician practices. The 
results were published in 2007 and summarized findings based on a sample size of 404 
Americans comparing black and white patients.20 Responders were mostly women (73%) 
and white (68%), with a mean age of 73 years in both groups. The study found that black 
11 
 
NSAID users were more likely to belong to a lower socio-economic status (cut-off was 
selected at annual household income of $20,000). The likelihood of living in a rural 
residence did not differ between black and white NSAID users.20 
While higher doses of NSAIDSs are obtained through a medical prescription, several 
lower dose NSAIDs can be purchased over-the-counter without a prescription. A study of 
229 447 French patients described and compared the characteristics of over-the-counter 
and prescription NSAID users. About 52% of patients in the study received at least one 
prescription for a NSAID. Compared to over-the-counter NSAID users, prescription 
strength NSAID users were older (mean age 39.9 vs. 47.4), and were more likely to have 
at least one long-term illness (18.9% vs. 27.6) (conditions considered as long-term 
illnesses included stroke, severe arterial hypertension, coronary artery disease, severe 
heart failure, arrhythmia, heart valve disease, and congenital heart defects). Both groups 
had similar portions of women (56.7% versus 53%).81 
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Chapter 3  
3 Rationale 
3.1 TMA association with NSAID usage 
We performed a comprehensive review of the literature to summarize the current state of 
evidence regarding the association between TMA and NSAID exposure. We used the 
bibliographic databases Pubmed, EMBASE, Google Scholar, and Web of Science. Our 
search strategy for each database is described in appendix A. We identified 8 case reports 
suggesting a possible link between TMA and NSAID usage. 
Several generic methods have been used to assess the quality of reports to gain insight 
into the potential causality of an adverse drug event (e.g. Naranjo, Jones). No measure 
has been shown to better than the others, and in most cases the measure results in a 
conclusion that the drug has a ‘possible’ or ‘probable’ chance of causing the adverse drug 
event.82,83 
In our case, we evaluated the quality of the 8 case reports using an existing framework to 
assess drug-induced TMA (see appendix B). The results of this appraisal are found in 
table 1. In summary, TMA development was linked to Ibuprofen in 4 cases.8–10,84 None of 
the 4 patients reported exposure to other risk factors for TMA, and exhibited telltale signs 
of TMA including hemolytic anemia, a low platelet count, acute kidney injury, an altered 
mental state, and low ADAMTS13 levels. Another published case report study of a 58-
year old woman described a possible link between ketorolac trometamol and TMA.12 One 
13 
 
case report published by Trice et al. attributed TMA development in a 64-year old man to 
treatment with D-penicillamine (an antibiotic); however, the patient had received 
naproxen (an NSAID) prior to receiving D-penicillamine.85 The NSAIDs diclofenac and 
pranoprofen were each reported to be associated with TMA in two separate case 
reports.13,86 In a review of DITMA, Al-Nouri et al. listed 2 case reports of ibuprofen and 
ketorolac under immune-mediated TMA in their supplementary table S3.7 These case 
reports were captured within the scope of our literature review.  
Beyond the published literature, we searched the European Database and Suspected 
Adverse Drug Reaction Reports, which records reports from the European Economic 
Areas (EEA). Collectively, there were a total of 54 cases of TMA with an NSAID 
identified as a suspected cause. Ibuprofen accounted for the majority of these cases (40), 
followed by diclofenac (12) and naproxen (2). The age of these patients ranged from less 
than 1 year to over the age of 65. We also searched (i) Health Canada’s Canada Vigilance 
Program database and (ii) the Food and Drug Administration’s Adverse Event Reporting 
System (FAERS) database, but these searches did not yield any reports. We recognize we 
have may have missed potentially reports of interest within these databases, given our 
limited level of access and difficulties with how the data are organized.  
We contacted manufacturers of NSAIDs (Pfizer, Novartis, and Bayer) via telephone 
and/or e-mail to inquire whether they had any documented cases of TMA associated with 
their NSAID drugs. Whenever a valid response was received, we were simply referred to 
publicly available information that we had already reviewed.  
14 
 
It appears the current evidence supporting an association between NSAIDs and TMA is 
limited to case report studies. While case reports are helpful in detecting novel events and 
are hypothesis generating, they are limited in eliciting cause and effect relationships, and 
they are also limited by several forms of bias and poor generalizabilitys.87 We were 
unable to perform an in-depth review of two of the eight reports due to language barriers 
(one report was written in Italian and one report was written in Spanish) and limited 
access to full articles (the articles were published in 1974 and 1989). The reports have 
been referenced in more recent case reports but a detailed analysis of the reports was not 
made.   
Five of the remaining six studies reviewed did not document an alternative condition or 
drug exposure which could have led to TMA, and it was not clear from the report 
whether discontinuation of the NSAID (or a reduced dose of NSAID) was followed by an 
improvement in TMA symptoms. 
None of the case reports provided information as to whether reintroduction of a NSAID 
after a TMA episode resulted in a TMA reoccurrence.  
Furthermore, the potential pathophysiologic mechanism by which of NSAIDs may cause 
TMA is not well understood. Some have hypothesized that the potential association 
between TMA and NSAID lies within the formation of autoantibodies against 
ADAMTS13.84  
Thus, an important gap exists in the literature with respect to the possible link between 
NSAIDs and TMA.  
15 
 
 
3.2 Research objective and hypothesis 
This study was conducted to investigate whether a TMA hospitalization was more likely 
to be associated with a recent prior prescription for NSAID compared to a recent prior 
prescription of acetaminophen, the latter being the referent drug with no known 
association with TMA. To address this objective, we conducted a retrospective matched 
case-control study using health administrative data in the province of Ontario. Given the 
current state of evidence, we hypothesized that exposure to NSAIDs, relative to 
acetaminophen, would be associated with a higher incidence of TMA. 
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Table 1.  
Case report evaluation for NSAID associated TMA 
NSAID Citation Year 
published 
Patient sex 
and age in 
years 
Level of 
evidence1 
Diclofenac Claros González I, Baños 
Gallardo M, Casal Alvarez F, 
Argüelles Toraño M. 
Systemic thrombotic 
microangiopathy secondary 
to diclofenac. Med Clínica. 
1989;92(10):396. 
1989 Male, 
middle aged 
5 
Ibuprofen Catizone L, Santoro A, 
Scialfa G, Cagnoli L, Fabbri L. 
Thrombotic 
thrombocytopenic purpura 
due to administration of 
Ibuprofen. Minerva Nefrol. 
1974;21(6):439-444. 
1974 Female, 55 5 
Ibuprofen Schoenmaker NJ, Weening 
JJ, Krediet RT. Ibuprofen-
induced HUS. Clin Nephrol. 
2007;68(3):177-178. 
2007 Female, 44  2 
Ibuprofen Oregel KZ, Ramdial J, Glück 
S. Nonsteroidal Anti-
inflammatory Drug Induced 
Thrombotic 
2013 Male, 21 2 
17 
 
Thrombocytopenic Purpura. 
Clin Med Insights. 
2013;6:19-22. 
doi:10.4137/CMBD.S12843. 
Ibuprofen Benmoussa J, Chevenon M, 
Nandi M, Forlenza TJ, 
Nfonoyim J. Ibuprofen-
induced thrombotic 
thrombocytopenic purpura. 
Am J Emerg Med. 
2016;34(5):942.e5-e7. 
doi:10.1016/j.ajem.2015.10.
044. 
2016 Male, 37 2 
Ketorolac 
Tromethamine 
Randi ML, Tison T, Luzzatto 
G, Girolami A. Haemolytic 
uraemic syndrome during 
treatment with ketorolac 
trometamol. BMJ. 
1993;306(6871):186. 
1993 Female, 58 2 
Naproxen Trice JM, Pinals RS, Plitman 
GI. Thrombotic 
thrombocytopenic purpura 
during penicillamine 
therapy in rheumatoid 
arthritis. Arch Intern Med. 
1983;143(7):1487-1488. 
doi:10.1001/archinte.1983.
00350070215039. 
1983 Male, 64 3 
18 
 
Pranoprofen Okura H, Hino M, Nishiki S, 
et al. Recurrent hemolytic 
uremic syndrome induced 
by pranoprofen. Rinsho 
Ketsueki. 1999;40(8):663-
666. 
1999 Female, 25 2 
1 Case reports are given a level from 1 to 5 depending on how many causal criteria the case fulfills; 1 = 
definite evidence of a causal relationship, 2 = probable, 3 = possible, 4 = unlikely, 5 = unsuitable for 
review. A more detailed explanation is provided in appendix B. 
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Chapter 4  
4 Methods 
4.1 Study design and setting  
We conducted a retrospective matched case-control study using administrative data in the 
province of Ontario, linked at the Institute of Clinical Evaluative Sciences (ICES). Cases 
(individuals who were hospitalized for TMA between 1996 and 2015) and controls 
(described below) were identified from a source population of Ontario residents who (i) 
were prescribed NSAIDS or acetaminophen between 1996 and 2015 and (ii) had 
universal drug coverage during this time (in Ontario, universal drug coverage is granted 
to Ontario residents who are older than age 65, to those living in a long-term-care facility 
or a home for special care, and to those enrolled in the Home Care program, the Trillium 
Drug Program, Ontario Works, or the Ontario Disability Support Program). We selected 
this study design given TMA is a rare disease.  
This study was conducted according to a pre-specified protocol, which was approved by 
the Research Ethics Board at the Sunnybrook Health Sciences Centre in Toronto, 
Ontario. The reporting of the study adheres to the Reporting of studies Conducted using 
Observational Routinely-collected Data (RECORD) guideline (appendix C).  
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4.2 Data sources 
This study was conducted using administrative healthcare databases linked at the ICES 
Western site in London, Ontario. The study was conducted primarily using the following 
four databases: 
1) Registered Persons Database  
The Registered Persons Database (RPDB) is a population-based registry managed by the 
Ministry of Health and Long-Term Care (MOHLTC) in Ontario, Canada. The RPDB is 
essentially a comprehensive listing of the unique health numbers that have been issued to 
individuals eligible for coverage since its conception, and the purpose of the database is 
to direct publicly funded health care services covered under the Ontario Health Insurance 
Plan. When new RPDB data arrive at ICES, information regarding a potential patient’s 
identity is removed and each unique health number is encrypted into an anonymous 
identifier, the ICES Key Number (IKN). The IKN is a unique identifier that is used to 
link patient data across databases in ICES. We used the RPDB database to obtain 
demographic information including a patient’s date of birth, sex, income categories 
(sorted into 5 quintiles in order of ascending income levels), urban or rural residence 
status, and date of death. 
 
2) Ontario Drug Benefit 
The Ontario Drug Benefit (ODB) Program is a publicly funded program that provides 
financial assistance for medication costs. The ODB records all outpatient drug 
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prescriptions dispensed to patients who are eligible for this program, specifically, Ontario 
residents aged 65 years and older, those living in a long-term-care facility or a home for 
special care, and those enrolled in the Home Care program, the Trillium Drug Program, 
Ontario Works, or the Ontario Disability Support Program. We used this database to 
ascertain exposures to any of our study drugs and to any baseline medications. 
 
3) Canadian Institute for Health Information – Discharge Abstracts Database 
The Canadian Institute for Health Information – Discharge Abstract Database (CIHI-
DAD) contains patient-level demographic, diagnostic, medical procedural, and other 
administrative information (e.g. physician responsible for the patient) for hospitals across 
Ontario. The structure of the database allows an assignment of up to a maximum of 25 
diagnoses allocated to a single hospitalization event. Diagnoses made prior to 2002 are 
recorded using the International Classification of Diseases, ninth revision (ICD-9). Since 
then the tenth revision of the coding has been used to record diagnosis information. We 
used this database to identify all diagnoses of TMA from 1991 to the latest update, which 
includes up to March of 2015. We also used this database to ascertain information on 
baseline comorbidities. 
 
4) Ontario Health Insurance Plan 
The Ontario Health Insurance Plan (OHIP) database contains medical service claims 
made by healthcare professionals, including physicians, for patients who are residents of 
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Ontario. Ontario physicians are reimbursed for the services they are documented as 
providing to specific patients on specific days. The OHIP database records information 
such as the type of service provided, diagnostic information, the healthcare professional 
that provided the service, the patient who received the service, the date the claim was 
filed, and the associated fee code. It is estimated that 95% of physicians in Ontario utilize 
OHIP as their source of income. We used this database to identify any patients who 
received plasma exchange treatments between July 1991 to March 2015. 
 
4.3 Patient population selection 
Patients who had at least one prescription for an NSAID or acetaminophen dispensed 
through Ontario Drug Benefit (ODB) between July 1991 and March 2015 formed the 
study base for this case-control study. The data was subsequently linked to the Registered 
Persons Database (RPDB) and all patients with an invalid or missing value under the 
variables age, sex, or health card number (patient identifying number) were excluded. 
Next, we identified all hospitalizations with TMA through linkage to Canadian Institute 
for Health Information-Discharge Abstract Database (CIHI-DAD). As we were interested 
in new (de novo) episodes of TMA, we excluded patients with evidence of a TMA 
diagnosis or patients who received plasma exchange preceding July 1, 1996. The 
remaining patients consisted of cases with a hospitalization diagnosis of TMA as defined 
from CIHI-DAD (codes presented in appendix D), and potential controls that did not 
have a hospitalization diagnosis of TMA as defined from CIHI-DAD.  
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4.4 Index date 
Cases were assigned an index date representative of the initial date of their 
hospitalization for TMA. Index dates fell between July 1, 1996 and March 31, 2015. 
Since the remaining patients were not diagnosed with TMA, we sampled the distribution 
of index dates from the case population and randomly assigned index dates to the 
remaining non-TMA patients based on the same distribution of index dates as cases 
 
4.5 Study population 
4.5.1 Cases  
We identified all available Ontario patients from our study base with a hospital admission 
diagnosis of TMA between July 1, 1996 and March 31, 2015 (codes presented in 
appendix D). Patients were restricted to their first admission to a hospital with TMA 
diagnosis within our accrual period, and the initial hospitalization with a TMA diagnosis 
served as the index date for cases.  
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4.5.2 Controls  
All individuals from our study base without a TMA diagnosis during our accrual period 
were eligible to be selected as controls. Since patients without TMA did not have a date 
of diagnosis to serve as an index date, we randomly assigned an index date to the pool of 
potential controls based on the distribution of index dates in cases.  
Matching is defined as the pairing of cases and controls based on pre-specified 
characteristics in order to form similar, if not identical matched sets with respect to said 
characteristics.88 The purpose of matching in case-control studies is to increase a study’s 
efficiency by ensuring similarity in the distribution of variables between cases and 
controls, in particular, the distribution of potential confounders.88,89 We matched 4 
controls per case based on the following characteristics: age (± 2 years), sex, index date 
(<6 months), rural residence (population less than 10,000), neighborhood income 
quintile, and conditions and drugs associated with a higher risk of TMA: malignant 
hypertension, systemic lupus erythematosus, HIV, sepsis, and use of quetiapine, 
tacrolimus, sirolimus, cyclosporine, clopidogrel, and ticlopidine.  
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4.5.3 Exposure  
We were interested in patients who had a past prescription of NSAIDs or a past 
prescription for acetaminophen, an analgesic drug used for a similar indication but not 
suspected to be associated with TMA.  
 
We looked at patients who were exposed to either one, mutually exclusive exposures, to 
minimize confounding by indication. For the purposes of this study, patients prescribed 
an NSAID were classified as “exposed”, while patients prescribed an acetaminophen 
were classified as “unexposed”. Index dates served as the point in time from when we 
looked back in time to ascertain exposure, where the drug supply period of the most 
recently dispensed NSAID or acetaminophen overlapped with the index date. The 
window of time in which we ascertained drug exposure was defined by the variable “day 
supply” in ODB, extended by 50%. For example, if a patient had received a prescription 
for 30 days worth of drug supply for NSAID or acetaminophen, we would look to see if 
they had been hospitalized with TMA within 45 days (30 days + 50%) of the date of 
prescription. Given the way we constructed the study sample to efficiently pull data from 
our data sources, it was expected we would have a substantial number of patients with no 
evidence of an NSAID or acetaminophen dispensed just prior to the index date (i.e. they 
had an NSAID or acetaminophen filled between July 1996 and March 2015, but this was 
well before or after their index date); such patients were excluded from analysis.  
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Patients with evidence of both an NSAID and acetaminophen were excluded from the 
analysis so that we could compare mutually exclusive groups.  
 
4.6 Baseline characteristics 
Baseline characteristics were assessed using ICD-9 and ICD-10 codes within the five 
years prior to the index date, with the exception of primary care physician visits being 
assessed in the year prior to the index date (but not in the 30-day period before the index 
date to avoid physician encounters possibly related to the TMA; database codes used to 
define characteristics are presented in supplementary appendix 2). Baseline outpatient 
drug use was ascertained in 120-day period before the index date, as in Ontario the 
maximum day supply for a dispensed drug is 100 days.  
 
4.7 Comorbidity indices 
Comorbidity can be referred to as the simultaneous existence of disease conditions other 
than the disease or outcome of interest. Comorbidity indices are designed to reflect 
comorbid burden, which can be used to predict mortality or adjust for as potential 
confounders in epidemiological studies.90,91 We considered implementing the Charlson 
Comorbidity Index and the John Hopkins Aggregated Diagnostic Groups. The Charlson 
Comorbidity Index measures general comorbidity based on the presence of a combination 
of diseases for a specific patient. Patients receive scores corresponding to a diagnosed 
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disease, the cumulative scores of all relevant diagnosed diseases represents their 
individual Charlson Comorbidity Index. A score of 1 is assigned to the following 
conditions: myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective 
tissue disease, peptic ulcer disease, mild liver disease, and diabetes. A score of 2 is 
assigned to the following conditions: hemiplegia, moderately severe renal disease, 
diabetes with organ damage, any tumors within the last 5 years, lymphoma, and 
leukemia. A score of 3 is assigned to moderately severe liver disease. Finally, patients 
diagnosed with acquired immune deficiency syndrome (AIDs) or metastasized tumors are 
assigned a score of 6. 90–93 John Hopkins Aggregated Diagnostic Groups features 32 
diagnostic clusters called aggregated diagnostic groups (ADGs), and each disease is 
categorized into one of the 32 clusters based on: duration of the condition, severity of the 
condition, disease etiology, diagnostic certainty, and specialty care involvement. 
Similarly, all baseline conditions are categorized and a cumulative score is derived to 
represent risk of mortality.94 Both techniques have been modified to utilize ICD codes for 
scoring.91,94 Austin et al. published a study in 2011 that showed superior performance in 
model discrimination and calibration for John Hopkins ADG scores as compared to the 
Charlson Comorbidity Index.95 This study was performed using the same Ontario datasets 
analyzed in our study. For this reason we decided to use the John Hopkins ADG score for 
this study.  
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4.8 Statistical analysis 
We assessed balance of baseline characteristics between case and control groups using 
hypothesis testing and standardized differences. Hypothesis testing operates on the null 
hypothesis that there are no critical differences between one group over another in terms 
of a specific treatment or condition. With respect to baseline assessment, we are testing if 
there is evidence to refute the null hypothesis (i.e. if there are indeed differences in means 
or proportions between cases and controls) across our selected baseline characteristics.96 
The p-value is widely used in hypothesis testing and describes the probability of 
obtaining an observation as large as the observed, had the null hypothesis been true. A p-
value of <0.05 can represent considerable evidence against the null hypothesis.97 Another 
method we used to compare baseline characteristics is the standardized difference. The 
standardize difference statistic measures differences between group means with respect to 
pooled standard deviation. A value of greater than 10% or 0.01 can be interpreted as a 
meaningful difference between two compared groups.98–100 We initially considered using 
standardized differences for its advantageous properties over hypothesis testing in studies 
with large sample sizes, however, this was not an issue with the current study.99,100 
Therefore, we selected to report p-values over standardize differences. We implemented 
generalized estimating equations (GEE) to assess baseline balance between cases and 
controls.101 
Logistic regression is fundamentally used to model the relationship between a binary 
dependent variable and a series of independent variables, but the method can be tailored 
to fit the nature of the data that is to be analyzed.102,103 We used conditional logistic 
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regression to obtain odds ratios, which provides an effect estimate of the likelihood of 
having a recent prescription for an NSAID among patients who were hospitalized with 
TMA (binary dependent variable) relative to acetaminophen. Conditional logistic 
regression is commonly selected as the statistical analysis when matching is done in a 
case control study.104 The main reason for this selection is to provide an estimate that is 
less susceptible to the effects of sparse data created by forming multiple strata of matched 
pairs as seen in our study.105  
We conducted all analyses using SAS version 9.3 (SAS institute, Cary, North Carolina, 
USA, 2008) 
 
4.9 Additional analyses 
We repeated the analysis with the referent drug hydromorphone instead of 
acetaminophen. The purpose of this analysis was to replicate the results of the primary 
analysis, as agreement between the two would increase our confidence in the findings. 
There is no known association between hydromorphone and TMA.  
Another consideration is that some NSAIDs (i.e. ibuprofen) are readily accessible over 
the counter and without a physician’s prescription. Exposure to over the counter non-
prescription NSAID use in the referent group would reduce differences in exposure 
between our comparison groups and reduce our ability to detect a higher risk of TMA 
with NSAIDs if an association had indeed existed. This is described as contamination 
bias, where the patients in the acetaminophen group were inadvertently exposed to 
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NSAIDs, thus diminishing the difference in outcomes between the two exposures.106 To 
limit the risk of contamination bias we repeated the analysis with the referent drug as an 
ACE-inhibitor instead of acetaminophen, as we expected less over the counter NSAID 
use in the setting of ACE-inhibitor use (as using both drugs together is often avoided).  
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Chapter 5  
5 Results 
5.1 Source population and selection of cases and controls 
The steps in patient selection are summarized in Figure 1. In brief, the source population 
consisted of 3,598,154 individuals who had evidence of a prescription dispensed for 
either a study NSAID or acetaminophen at least once anytime between July 1991 and 
March 2015, but after we excluded those with invalid or missing age, sex, and Ontario 
health card numbers. Next, we excluded 28 individuals with a TMA diagnosis prior to 
July 1996. Another 3,673 individuals were excluded due to their receipt of plasma 
exchange (939 prior to 1996; after the index date was assigned, 2,734 recipients of 
plasma exchange prior to 6 months before their index date). Of the remaining population 
of patients (n=3,598,154), we excluded 3,344,893 patients because their index date did 
not fall within the duration of their day supply extended by 50% (i.e. they had their 
NSAID or acetaminophen dispensed well before or after their index date), and we 
excluded 18,282 patients who had an index day fall within the duration of supply of both 
a study NSAID and acetaminophen. The patient population prior to matching consisted of 
44 cases and 231,234 potential controls. Patients were ‘hard’ matched on binary variables 
and for categorical variables (i.e. case and control must have same output). Ultimately, 
we were able to match 38 cases of TMA to 152 controls without TMA (1:4) for a final 
study population of 190 patients.  
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We performed some descriptive analyses to understand the clinical context of this 38 
TMA cases. To comply with privacy regulations for minimizing the chance of patient 
identification, cells between 1-5 patients are suppressed (reported as ≤5). Cells with a 
value of 0 are reported, as there is no one who could be identified. The TMA cases 
occurred across 28 different hospitals in Ontario. Within 90 days of their index hospital 
admission, 16 of 38 cases (42%) received at least one treatment with PLEX, 6 of 38 
(16%) received at least one treatment with dialysis, ≤5 (≤ 13%) of 38 were admitted to an 
intensive care unit, and ≤5 (≤ 13%) of 38 died.  
 
5.2 Baseline characteristics 
A comparison of baseline characteristics in cases and controls is presented in Table 2. 
The average age of patients was 67, and women accounted for two-thirds of the study 
sample. Given that we matched on several baseline characteristics, cases and controls 
were similar on most characteristics (p-value > 0.05). However, there were observed 
differences between cases and controls on the number of visits to a primary care 
physician in the year prior to the patient’s index date, and on the John Hopkins 
Aggregated Diagnosis Group Score.  
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5.3 Primary analysis 
19 cases (50%) were exposed to an NSAID and 19 cases (50%) were exposed to 
acetaminophen. 
The results of the regression analyses comparing TMA among patients prescribed 
NSAIDs vs. acetaminophen are presented in Table 3. Patients who were hospitalized with 
TMA were less likely to have received NSAIDs compared to acetaminophen (odds ratio 
[OR] 0.32, 95% confidence interval [CI] 0.15 – 0.68). Adjusting for baseline 
characteristics that differed between cases and controls did not meaningfully change this 
result (table 3; OR 0.37, 95% CI 0.16 – 0.84). 
 
5.4 Additional Analyses 
We wanted to determine if the reintroduction of NSAIDs after a TMA episode resulted in 
reoccurrence of the TMA. We found that of the 19 cases that had NSAIDs prior to their 
first TMA episode, 8 (42.1%) received a repeat prescription for NSAIDs in the year 
following their TMA-associated discharge date. None of these patients had a re-
hospitalization with TMA in the 30 days after the follow-up prescription.   
We used the active comparator (reference group) acetaminophen in this study, to reduce 
concerns about confounding by indication. However, this has implications for the 
interpretation of study results. For example, patients who were hospitalized with TMA 
were less likely to have received NSAIDs compared to acetaminophen (odds ratio [OR] 
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0.32, 95% confidence interval [CI] 0.15 – 0.68). This can be interpreted in several ways, 
including that NSAIDs are ‘protective’ in preventing TMA, acetaminophen is ‘harmful’ 
in causing TMA, acetaminophen is more ‘harmful’ than NSAIDs in causing TMA, or 
acetaminophen is less ‘beneficial’ than NSAIDS in preventing TMA, although most of 
these possibilities are not supported by our underlying understanding of the biology of 
TMA. However, to consider the results in other contexts we repeated the analysis twice 
with either hydromorphone or angiotensin converting enzyme inhibitors (ACE-I) (and not 
acetaminophen) as the reference group. 
 
5.4.1 Hydromorphone comparator group 
A new data cut was performed for this analysis to create a source population consisting of 
individuals with an evidence of prescription filling for NSAIDs or hydromorphone. The 
exclusions and cohort selection methods were as done for the primary analysis, 
comparing NSAIDs to acetaminophen. Ultimately, fewer than six cases were exposed to 
hydromorphone, which precluded us from presenting the results of this analysis due to 
privacy considerations; however, there was no observed association between NSAID use 
and TMA when the referent group was hydromorphone. The limited statistical power of 
this analysis meant the estimate was likely not precise enough to be considered 
meaningful.    
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5.4.2 Angiotensin-converting enzyme inhibitor (ACE-I) 
comparator group 
This supplementary analysis was done to reduce concerns about over-the-counter NSAID 
use in the control group (as NSAIDs are often avoided in the setting of ACE-I use). In a 
similar fashion to our other supplementary analysis, a new data cut was performed in 
order to create a source population of patients with evidence of a prescription filled for 
NSAIDs or ACE-Is. The exclusions and cohort selection methods were identical to that 
of the primary analysis, comparing NSAIDs to acetaminophen. The figures and tables 
corresponding to patient selection, baseline characteristics, and analysis output can be 
found in appendix E, F, and G respectively.  
In brief, the source population consisted of 3,442,246 individuals. Patients with a past 
diagnosis for TMA (n=80), and history of evidence for plasma exchange (n=3,392) were 
excluded. In ascertaining exposure, it was determined that 2,858,914 individuals were not 
exposed to either class of study drugs and 49,896 individuals were exposed to both 
classes of study drugs simultaneously. Exposure definitions were as done for the primary 
analysis. After matching, the final study population consisted of 84 cases matched to 336 
controls.  
The mean age of patients in the study population was 73. Females accounted for roughly 
60% of the study population.  
There was no observed association between NSAID use and TMA when the referent 
group was ACE-I (odds ratio 0.82, 95% CI 0.45-1.49; selection, baseline characteristics 
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and outcomes presented in appendices 3, 4 and 5, respectively). We performed an 
analysis adjusting for differences in baseline characteristics (more specifically: cancer, 
osteoarthritis, rheumatoid arthritis, John Hopkin’s ADG score and primary care physician 
visits), but did not observe a meaningful change in the results (odds ratio 0.72, 95% CI 
0.38-1.37).  
Figure 1. Flow diagram of patient selection with acetaminophen as the referent 
group 
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Table 2. Baseline characteristics for patients prescribed NSAIDs or acetaminophen 
with and without thrombotic microangiopathy (cases and controls, respectively) 
 
Controls 
(n=152) 
Cases (n=38) P-value 
Demographics 
Age, no. (%) 
Median (IQR) 71 (65-79) 71 (61-78)  
Mean ± SD 67 ± 16.11 67  ± 16.75 0.47 
16 - 34 9 (5.9%) ≤5 
0.23 
35 - 44 8 (5.3%) ≤5 
45- 54 7 (4.6%) ≤5 
55 - 64 11 (7.2%) ≤5 
65 - 74 61 (40.1%) 15 (39.5%) 
75 - 84 45 (29.6%) 9 (23.7%) 
≥ 85 11 (7.2%) ≤5 
Women, no. (%) 96 (63.2%) 24 (63.2%) 1.0 
Rural residence2, no. (%) 32 (21.1%) 8 (21.1%) 1.0 
Socioeconomic status3, no. (%) 
Quintile 1 28 (18.4%) 7 (18.4%) 1.0 
Quintile 2 52 (34.2%) 13 (34.2%) 1.0 
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Quintile 3 + 45 40 (26.4%) 10 1.0 
Quintile 5 32 (21.1%) 8 (21.1%) 1.0 
Primary care physician visits, no. (%) 
Median (IQR) 19 (5-15) 14 (7-23)  
Mean ± SD 12 ± 11.98 19 ± 17.06 <0.05 
0 - 2 16 (10.5%) ≤5 
<0.05 
3 - 4 20 (13.2%) ≤5 
5 - 6 24 (15.8%) ≤5 
7 - 8 14 (9.2%) ≤5 
9 - 10 15 (9.9%) ≤5 <0.05 
 ≥ 11 63 (41.4%) 23 (60.5%) 
Comorbidities, no. (%) 
John Hopkins Aggregated Diagnosis Group Score, no. (%) 
Median (IQR) 12 (9-15) 14 (12-16)  
Mean ± SD 12 ± 3.77 14 ± 3.43 <0.05 
≤ 9 44 (28.9%) 
10 (26.3%)5 
<0.05 
10 - 12 41 (27%) 
13 - 15 42 (27.6%) 14 (36.8%) 
≥ 16 25 (16.4%) 14 (36.8%) 
Malignant hypertension ≤5 ≤5 - 
Systemic lupus erythematosus ≤5 ≤5 - 
Cancer5 Suppressed ≤5 1.0 
Renal transplant ≤5 ≤5 - 
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1no.: Number, IQR: interquartile range, SD: Standardized difference, NSAIDs: Non-steroidal anti-inflammatory drugs. 
2Rural residence is defined as population < 10,000. 
3Quntiles are ranked from lowest to highest (i.e. Quintile 1 = lowest, Quintile 5 = highest). 
4P-values are calculated using generalized estimating equations to account for the non-independent correlation 
structure.  
5Cells are combined or suppressed to avoid reporting numbers ≤5. 
 
 
 
 
  
Osteoarthritis 12 (7.9) ≤5 0.59 
Rheumatoid arthritis 12 (7.9) ≤5 0.56 
HIV ≤5 ≤5 1.0 
Sepsis ≤5 ≤5 1.0 
Medications, no. (%) 
Quinine ≤5 ≤5 - 
Quetiapine ≤5 ≤5 - 
Tacrolimus ≤5 ≤5 - 
Sirolimus ≤5 ≤5 - 
Cyclosporine ≤5 ≤5 - 
Clopidogrel ≤5 ≤5 - 
Ticlopidine ≤5 ≤5 - 
40 
 
Table 3. The association between NSAID use and thrombotic microangiopathy, with 
acetaminophen as a reference group. Odds ratios derived from a conditional logistic 
regression model 
 
Cases of 
TMA 
(n=38) 
Controls 
(n=152) 
Odds Ratio (95% confidence interval) 
Unadjusted Adjusted1 
Acetaminophen  19 (50%) 37 (24%) 1.0 (referent) 1.0 (referent) 
NSAIDs2 19 (50%) 115 (76%) 0.32 (0.15 – 0.69) 0.37 (0.16 – 0.84) 
1Adjusted analysis included the variables John Hopkin’s ADG score and primary care physician visits.  
2NSAIDs: Non-steroidal anti-inflammatory drugs. 
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Chapter 6  
6 Discussion 
6.1 Interpretation of study results 
There are over 30 million daily users of NSAIDs worldwide, and there is some evidence 
from case-report studies that patients who present with TMA have a recent history of 
NSAID use.1,2 We conducted this matched case-control study to better understand 
whether NSAID use is associated with a higher risk of hospitalization for TMA. We 
found that cases with TMA were less likely to have had a recent prescription for NSAIDS 
relative to acetaminophen. More specifically, we observed that the case patients were 
nearly 3 times (OR: 0.37) less likely to be exposed to an NSAID relative to 
acetaminophen. Furthermore, this association was statistically significant (95% CI: 0.16 – 
0.84). We found no association between NSAID use and TMA when we examined two 
alternate reference groups. For example, when we compared NSAIDs to ACE-inhibitors, 
we observed no significant association [OR of 0.72 (95% CI: 0.38 – 1.37)]. Ultimately, 
we were unable to provide any evidence to support a harmful association between 
NSAIDs and TMA.  
Our findings prompted us to re-examine the case reports.7–10,12,13,85 The most common 
reason the reports suggested NSAIDs as the cause of TMA was simply because there was 
no other identified cause present. Furthermore, no research to date provides a strong 
biological basis for a higher risk of TMA with NSAIDs. This would indicate that, at the 
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very least, NSAIDs are not associated with a higher risk of TMA, which is consistent 
with our findings. 
None of the case reports addressed the topic of re-introduction of an NSAID after an 
episode of TMA. It would be concerning if NSAID use after a TMA episode resulted in 
TMA reoccurrence. In our study, we found that 8 (42.1%) exposed cases received a 
repeat prescription for NSAIDs in the year following their TMA-associated discharge 
date. No patient was re-hospitalized with TMA in the 30 days after the follow-up NSAID 
prescription. Thus, these data do not support avoiding NSAID use in patients with a prior 
history of TMA.  
 
6.2 Strengths and limitations 
Since TMA is a rare event (< 1 per 100,000)21,22,27, our use of large healthcare databases 
in the largest province in Canada was opportune as we captured all TMA cases for the 
entire province of Ontario over two decades. Methodologically, the case-control design is 
considered to be stronger than the case-series design and weaker than the cohort study 
design, but we chose to implement the case-control design for this rare disease in order to 
identify all available cases and maximize statistical power107 To our knowledge, our 
study is the first study to explore an association between NSAIDs and TMA using 
population-based administrative data.  
However, as with all observational studies, our results are subject to residual 
confounding. Even though we controlled for many well-known risk factors for TMA and 
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important indications of NSAID use, not all the characteristics are well-coded in our data 
sources, which were collected for the primary purpose of healthcare administration rather 
than research. To the best of our knowledge, the ICD-9 and ICD-10 codes for TMA have 
not yet been validated in any setting. Generally, codes representing administrative data 
are typically highly specific, and vary widely in sensitivity.108  
The clinical severity of TMA warrants immediate diagnosis and prompt treatment. Most 
patients who develop TMA would present to hospital due to acute illness. To reduce the 
risk of early mortality, treatment is initiated in hospital upon an early suspicion of 
TMA.30,109,110 Without treatment most TMA is fatal. It remains possible that some TMA 
goes undiagnosed in routine care, where a patient dies before a diagnosis is made (either 
before or during a hospitalization). It is an inherent limitation of this study that such cases 
of TMA were not assessed.30 
Other consequences that are inevitably associated with the use of administrative data 
affected how we defined our outcomes, comorbid conditions, and overall selection of 
patients. Furthermore, our data only informs us as to whether the patients had an oral 
prescription dispensed, which does not necessarily equate to drug ingested.  
One of the biggest challenges in the design of a case-control study is selecting the 
appropriate patient population to draw cases and controls.111 We conducted a case-control 
study within a population of patients exposed to common pain-indicated drugs, which 
would have eliminated some uncertainty around the source we sampled our cases and 
controls. However, this approach is not without its flaws. The results obtained from such 
a case-control study cannot discriminate an association between the two exposures.112 
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Using the results of this study as an example, we obtained a statistically significant odds 
ratio that suggests an association exists between NSAIDs and TMA, and this association 
was protective. On the other hand, the result can also be interpreted as a harmful 
association between acetaminophen and TMA. More research is required before any 
conclusions may be drawn regarding the protective association of NSAIDs or the harmful 
association with acetaminophen. Nevertheless, our hypothesis had been that a harmful 
association would exist between NSAIDs and TMA, with no prior reason to believe 
acetaminophen use alters TMA risk. A case-control study of pharmacological 
contraceptives presented in Weiss and Koepsell, 2014 utilized a similar study design.112 
The study consisted of entirely oral contraceptive users. However, elements of such a 
case-control study is commonly found in nested case-control studies, which is 
differentiated by the use of incidence-density sampling in selecting matched controls.113 
It is important to note that the study is susceptible to inadequate power to detect a true 
effect. Larger sample sizes are generally necessary to accurately ascertain a suspected 
difference between comparator groups, which is closer to the true effect with increasing 
power.114 However, it is also important to note that low power can increase the chance of 
observing a statistically significant effect where in truth none had existed.115 The effect 
estimate in our primary analysis was statistically significant (95% CI did not cross 1, or 
the estimate of no difference in effect). However, the confidence interval was quite wide 
(0.16 – 0.84). Wide confidence intervals are a telling feature that the estimates lack 
precision and that an analysis likely suffers from low power.116 
Another limitation of our study, on the topic of small sample size, is in how we can 
control for potential confounders. While we may have deferred to a method of selecting 
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confounders based on significance level of each variable (e.g. forward selection, 
backwards elimination, or a hybrid method)117, we recognized that we were limited by 
our small sample size and placed more reliance on matching to ensure that the 
distribution of potential confounders were similar between cases and controls.  
Nonetheless, we attempted to control for all potential confounders within the constraints 
of a relatively small sample size.  
While we included patients of all ages, the majority of information gathered from the 
Ontario Drug Benefit database was limited to patients older than age 65. This was 
apparent in the median age (71) of our cohort. Therefore, our results may not generalize 
to younger age groups.  
 
6.3 Conclusion and future directions   
In conclusion, the results of this study did not provide evidence supporting a harmful 
association between NSAIDs and TMA.  
Historically, case reports and small observational studies have been key to advancing 
TMA treatments. Initial observations of TMA symptoms were largely reported in isolated 
cases, dating as far back as 1925. Since then there have been a series of studies with 
small sample sizes (n<15) noting the efficacy of various treatments, until the literature 
began to converge on the success of plasma exchange therapy, eventually leading to a 
randomized control trial of 102 TMA patients; this trial clearly demonstrated the 
superiority of plasma exchange therapy compared to plasma infusion.118 Convincing 
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results from case reports and small observational studies are important for hypothesis 
generation and set the precedence for clinical trials. We also believe in the value of 
observational studies for identifying strong candidates for biological studies on the 
etiology, pathogenesis, and pathophysiology of TMA. Therefore, additional studies on 
DITMA in different populations and/or settings could provide further evidence of an 
potential association between NSAIDs and TMA, generate hypotheses for future studies, 
and strengthen the current state of evidence which consists predominately of case reports. 
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Appendices 
Appendix A: Search strategy summary   
Database Search strategy 
Pubmed 
1. Search (((Anti-Inflammatory Agents, Non-
Steroidal) OR NSAID*)) 
2. Search ((((Thrombotic Microangiopathy) OR 
Microangiopathies, Thrombotic) OR 
Microangiopathy, Thrombotic)) 
3. Search (thrombotic thrombocytopenic purpura) 
OR TTP 
4. Search (hemolytic uremic syndrome) OR HUS 
5. 2 OR 3 OR 4 
6. 1 AND 5 
 
Embase 
1. Thrombotic microangiopathy.mp. OR thrombotic 
thrombocytopenic purpura/ 
2. Hemolytic uremic syndrome/ 
3. NSAID.mp. OR nonsteroidal anti-inflammatory 
agent/ 
4. 1 OR 2 
5. 3 AND 4 
Google Scholar Keyword search using “thrombotic microangiopathy”, 
“thrombotic thrombocytopenic purpura”, “hemolytic 
uremic syndrome”, “non-steroidal anti-inflammatory”, 
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and any alternative representations (e.g. NSAID).  
Web of Science 
1. TI=thrombotic thrombocytopenic purpura 
2. TI=Hemolytic uremic syndrome 
3. TS=Thrombotic microangiopathy  
4. TS=NSAID 
5. TS=non-steroidal anti-inflammatory 
6. 1 OR 2 OR 3 
7. 4 OR 5 
8. 6 AND 7 
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Appendix B:  
Criteria for evaluation of reports1 
1. Clinical or pathologic diagnostic criteria for TMA were present 
2. Clinically apparent causes of clinical/pathologic criteria other than TMA and causes of 
TMA other than drug toxicity were excluded AND the suspected drug was the only drug 
taken or other drugs were continued or restarted 
3. TMA resolved or improved when suspected drug stopped or dose reduced (kidney 
injury may persist) 
4. TMA worsened after suspected drug discontinued OR TMA recurred without 
subsequent drug exposure 
 
Levels of evidence for an association of the NSAID induced TMA 
Evidence Level Criteria met 
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Level 1 Definite 1, 2, and 3 
Level 2 Probable 1 and 2 
Level 3 Possible 1 
Level 4 Unlikely 1 and 4 
Level 52 Not suitable for review due to any one of following: 
1. No individual patient data reported 
2. Insufficient patient data for assessment 
3. Diagnostic criteria for TMA (1) was not met 
4. Inappropriate drug dose or non-therapeutic use  
5. Drug etiology neither proposed or discussed 
6. Combination drug etiology proposed 
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1Criteria for evaluation for this study is based on the criteria for evaluation used in Al-Nouri et al.7 for toxic-mediated drug induced 
TMA. Criteria for immune-mediate drug induced TMA was not utilized due to the differences in indication and pharmacological 
action between NSAIDs and drugs which are speculated and/or suspected to cause TMA through an immune-mediated mechanism 
(e.g. quinine).  
2We did not limit our literature search by language. Therefore, reports with an available English title and reports that were referenced 
via other literature were included and reviewed them according to these criteria, where possible. We were unable to review reports 
without access to full article. 
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Appendix C: The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in 
observational studies using routinely collected health data. 
 
 Item 
No. 
STROBE items Location in 
manuscript where 
items are reported 
RECORD items Location in manuscript 
where items are reported 
Title and abstract  
 1 (a) Indicate the 
study’s design with a 
commonly used term 
in the title or the 
abstract (b) Provide 
in the abstract an 
informative and 
balanced summary 
Title page, abstract, 
methods 
RECORD 1.1: The type of 
data used should be 
specified in the title or 
abstract. When possible, 
the name of the databases 
used should be included. 
 
Title page, abstract, methods 
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of what was done 
and what was found 
RECORD 1.2: If 
applicable, the geographic 
region and timeframe 
within which the study 
took place should be 
reported in the title or 
abstract. 
 
RECORD 1.3: If linkage 
between databases was 
conducted for the study, 
this should be clearly 
stated in the title or 
abstract. 
Introduction 
Background 
rationale 
2 Explain the scientific 
background and 
Introduction   Introduction  
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rationale for the 
investigation being 
reported 
Objectives 3 State specific 
objectives, including 
any prespecified 
hypotheses 
Introduction   Introduction  
Methods 
Study Design 4 Present key elements 
of study design early 
in the paper 
Methods  
Methods 
Setting 5 Describe the setting, 
locations, and 
relevant dates, 
including periods of 
recruitment, 
exposure, follow-up, 
and data collection 
Methods  Methods 
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Participants 6 (a) Cohort study - 
Give the eligibility 
criteria, and the 
sources and methods 
of selection of 
participants. 
Describe methods of 
follow-up 
Case-control study - 
Give the eligibility 
criteria, and the 
sources and methods 
of case 
ascertainment and 
control selection. 
Give the rationale 
for the choice of 
cases and controls 
Cross-sectional 
Methods RECORD 6.1: The 
methods of study 
population selection (such 
as codes or algorithms 
used to identify subjects) 
should be listed in detail. 
If this is not possible, an 
explanation should be 
provided.  
 
RECORD 6.2: Any 
validation studies of the 
codes or algorithms used 
to select the population 
should be referenced. If 
validation was conducted 
for this study and not 
published elsewhere, 
detailed methods and 
Methods 
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study - Give the 
eligibility criteria, 
and the sources and 
methods of selection 
of participants 
 
(b) Cohort study - 
For matched studies, 
give matching 
criteria and number 
of exposed and 
unexposed 
Case-control study - 
For matched studies, 
give matching 
criteria and the 
number of controls 
per case 
results should be provided. 
 
RECORD 6.3: If the study 
involved linkage of 
databases, consider use of 
a flow diagram or other 
graphical display to 
demonstrate the data 
linkage process, including 
the number of individuals 
with linked data at each 
stage. 
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Variables 7 Clearly define all 
outcomes, 
exposures, 
predictors, potential 
confounders, and 
effect modifiers. 
Give diagnostic 
criteria, if applicable. 
Methods, table 2, 
Appendix D 
RECORD 7.1: A complete 
list of codes and 
algorithms used to classify 
exposures, outcomes, 
confounders, and effect 
modifiers should be 
provided. If these cannot 
be reported, an explanation 
should be provided. 
Methods, table 2, appendix D 
Data sources/ 
measurement 
8 For each variable of 
interest, give sources 
of data and details of 
methods of 
assessment 
(measurement). 
Describe 
comparability of 
assessment methods 
if there is more than 
Appendix D, 
Methods 
 Appendix D, Methods 
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one group 
Bias 9 Describe any efforts 
to address potential 
sources of bias 
Methods, Results  Methods, Results 
Study size 10 Explain how the 
study size was 
arrived at 
Figure 1  Figure 1 
Quantitative 
variables 
11 Explain how 
quantitative 
variables were 
handled in the 
analyses. If 
applicable, describe 
which groupings 
were chosen, and 
why 
Methods, table 2  Methods, table 2 
Statistical 
methods 
12 (a) Describe all 
statistical methods, 
Methods, results, 
table 2, and table 3 
  Methods, results, table 2, and 
table 3 
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including those used 
to control for 
confounding 
(b) Describe any 
methods used to 
examine subgroups 
and interactions 
(c) Explain how 
missing data were 
addressed 
(d) Cohort study - If 
applicable, explain 
how loss to follow-
up was addressed 
Case-control study - 
If applicable, explain 
how matching of 
cases and controls 
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was addressed 
Cross-sectional 
study - If applicable, 
describe analytical 
methods taking 
account of sampling 
strategy 
(e) Describe any 
sensitivity analyses 
Data access 
and cleaning 
methods 
 ..  RECORD 12.1: Authors 
should describe the extent 
to which the investigators 
had access to the database 
population used to create 
the study population. 
 
RECORD 12.2: Authors 
Methods 
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should provide 
information on the data 
cleaning methods used in 
the study. 
Linkage  ..  RECORD 12.3: State 
whether the study included 
person-level, institutional-
level, or other data linkage 
across two or more 
databases. The methods of 
linkage and methods of 
linkage quality evaluation 
should be provided. 
Methods: data sources 
Results 
Participants 13 (a) Report the 
numbers of 
individuals at each 
stage of the study 
(e.g., numbers 
Figure 1 RECORD 13.1: Describe 
in detail the selection of 
the persons included in the 
study (i.e., study 
population selection) 
Figure 1 
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potentially eligible, 
examined for 
eligibility, confirmed 
eligible, included in 
the study, 
completing follow-
up, and analysed) 
(b) Give reasons for 
non-participation at 
each stage. 
(c) Consider use of a 
flow diagram 
including filtering based 
on data quality, data 
availability and linkage. 
The selection of included 
persons can be described 
in the text and/or by means 
of the study flow diagram. 
Descriptive 
data 
14 (a) Give 
characteristics of 
study participants 
(e.g., demographic, 
clinical, social) and 
information on 
exposures and 
Figure 1, table 2, 
methods 
 Figure 1, table 2, methods 
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potential 
confounders 
(b) Indicate the 
number of 
participants with 
missing data for each 
variable of interest 
(c) Cohort study - 
summarise follow-up 
time (e.g., average 
and total amount) 
Outcome 
data 
15 Cohort study - 
Report numbers of 
outcome events or 
summary measures 
over time 
Case-control study - 
Report numbers in 
Table 3  Table 3 
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each exposure 
category, or 
summary measures 
of exposure 
Cross-sectional 
study - Report 
numbers of outcome 
events or summary 
measures 
Main results 16 (a) Give unadjusted 
estimates and, if 
applicable, 
confounder-adjusted 
estimates and their 
precision (e.g., 95% 
confidence interval). 
Make clear which 
confounders were 
adjusted for and why 
Table 3, results  Table 3, results 
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they were included 
(b) Report category 
boundaries when 
continuous variables 
were categorized 
(c) If relevant, 
consider translating 
estimates of relative 
risk into absolute 
risk for a meaningful 
time period 
Other 
analyses 
17 Report other 
analyses done—e.g., 
analyses of 
subgroups and 
interactions, and 
sensitivity analyses 
Results   Results 
Discussion 
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Key results 18 Summarise key 
results with 
reference to study 
objectives 
Results   Results 
Limitations 19 Discuss limitations 
of the study, taking 
into account sources 
of potential bias or 
imprecision. Discuss 
both direction and 
magnitude of any 
potential bias 
Discussion RECORD 19.1: Discuss 
the implications of using 
data that were not created 
or collected to answer the 
specific research 
question(s). Include 
discussion of 
misclassification bias, 
unmeasured confounding, 
missing data, and changing 
eligibility over time, as 
they pertain to the study 
being reported. 
Discussion 
 
Interpretation 20 Give a cautious 
overall interpretation 
Discussion   Discussion 
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of results 
considering 
objectives, 
limitations, 
multiplicity of 
analyses, results 
from similar studies, 
and other relevant 
evidence 
Generalisabil
ity 
21 Discuss the 
generalisability 
(external validity) of 
the study results 
  Discussion 
Other Information 
Funding 22 Give the source of 
funding and the role 
of the funders for the 
present study and, if 
applicable, for the 
Acknowledgements   Acknowledgements 
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original study on 
which the present 
article is based 
Accessibility 
of protocol, 
raw data, and 
programming 
code 
 ..  RECORD 22.1: Authors 
should provide 
information on how to 
access any supplemental 
information such as the 
study protocol, raw data, 
or programming code. 
ICES data is not available to 
the public as it contains 
personal medical information  
 
*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the 
RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) 
Statement. PLoS Medicine 2015; in press. 
*Checklist is protected under Creative Commons Attribution (CC BY) license. 
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Appendix D: Codes 
 
Coding definitions for cohort build and baseline characteristics  
Variable Database Codes 
Cohort Selection 
TMA CIHI-
DAD 
ICD-9: “4466” 
 ICD-10: “M311”  
Plasma Exchange OHIP “G272”, “G277”, “G278”, “G290” 
NSAIDs ODB CELECOXIB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC 
SODIUM & MISOPROSTOL, DIFLUNISAL, ETODOLAC, 
FENOPROFEN CALCIUM, FLOCTAFENINE, FLURBIPROFEN, 
IBUPROFEN, INDOMETHACIN, KETOPROFEN, KETOROLAC 
TROMETHAMINE, MEFENAMIC ACID, MELOXICAM, 
NABUMETONE, NAPROXEN, OXAPROZIN, PIROXICAM, 
ROFECOXIB, SULINDAC, TIAPROFENIC ACID, TOLMETIN 
SODIUM, VALDECOXIB 
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Acetaminophen ODB ACETAMINOPHEN & CODEINE PHOSPHATE, ACETAMINOPHEN & 
CAFFEINE & CODEINE PHOSPHATE 
Dilaudid ODB HYDROMORPHONE, HYDROMORPHONE HCL 
ACE inhibitors ODB BENAZEPRIL CHLOROHYDRATE, BENAZEPRIL HCL, CAPTOPRIL, 
CILAZAPRIL, ENALAPRIL SODIUM, FOSINOPRIL, FOSINOPRIL 
SODIUM, LISINOPRIL, PERINDOPRIL TERT.BUTYLAMINE, 
QUINAPRIL, RAMIPRIL, TRANDOLAPRIL 
Baseline comorbidities 
Cancers  CIHI-
DAD 
OHIP 
ICD9 (CIHI-DAD): "150", "154", "155", "157", "162", "174", "175", "185", 
"203", "204", "205", "206", "207", "208", "2303", "2304", "2307", "2330", 
"2312", "2334" 
IDC10 (CIHI-DAD): "971", "980", "982", "984", "985", "986", "987", 
"988", "989", "990", "991", "993", "C15", "C18", "C19", "C20", "C22", 
"C25", "C34", "C50", "C56", "C61", "C82", "C83", "C85", "C91", "C92", 
"C93", "C94", "C95", "D00", "D05", "D010", "D011", "D012", "D022", 
"D075" 
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OHIP DX: "203", "204", "205", "206", "207", "208", "150", "154", "155", 
"157", "162", "174", "175", "183", "185" 
Kidney transplant CORR 
OHIP 
CORR: 
RECIPIENT_TREATMENT dataset 
 [Treatment_Code]: 171  
 [Treatment_Date]  
 [Transplanted_Organ_Type_Code][1-3]: "10", "11", "12", "18", "19" 
CCP: "6759" 
CCI: "1PC85" 
OHIP feecode: "S435", "S434" 
Rheumatoid arthritis  ICD9: "714" 
ICD10: "M05", "M06" 
OHIP Dx: "714" 
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Osteoarthritis CIHI-
DAD 
ICD9: "715" 
ICD10: "M15", "M150", "M151", "M152", "M153", "M154", "M158", 
"M159"  
Malignant hypertension CIHI-
DAD 
ICD9: "4010" 
ICD10: "I101" 
Systemic lupus 
erythematosus 
CIHI-
DAD 
ICD9: "7100" 
ICD10: "M320", "M321", "M328", "M329" 
HIV CIHI-
DAD 
OHIP 
ICD9 (CIHI-DAD): "042", "043", "044", "176" 
ICD10 (CIHI-DAD): "B24", "Z21", "C46" 
OHIP DX: "042", "043", "044" 
Sepsis CIHI-
DAD 
ICD9: "0031", "0362", "0380", "0381", "0382", "0383", "03840", "038.41", 
"03842", "03843", "03844", "03849", "0388", "0389" 
ICD10: "A40", "A41" 
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TMA: Thrombotic microangiopathy, NSAIDs: non-steroidal anti-inflammatory drugs, ICD: International Classification of Diseases, 
CIHI-DAD: Canadian Institute for Health Information – Discharge Abstract Database, OHIP: Ontario Health Insurance Plan, CORR: 
Canadian Organ Replacement Register, CCI: Canadian Classification of Health Interventions, CCP: Canadian Classification of 
Diagnostic, Therapeutic and Surgical Procedures, ACE: angiotensin-converting enzyme, HIV: Human Immunodeficiency Vir
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Appendix E: Flow diagram of patient selection with angiotensin-converting enzyme 
inhibitors as referent group 
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Appendix F: Baseline characteristics for patients prescribed NSAIDs1 or ACE-
inhibitors1 with and without thrombotic microangiopathy (cases and controls, 
respectively) 
 
Controls 
(n=336) 
Cases 
(n=84) 
P-value4 
Demographics 
Age, no. (%) 
Median (IQR) 74 (68-81) 74 (67-82)  
Mean ± SD 73 ± 10.4 73 ± 11.13 0.22 
≤ 17 
21 (6.3%)5 
0 
0.41 
18 - 44 0 
35 - 44 ≤5 
16 - 54 ≤5 
55 - 64 20 (6%) 7 (8.3%) 
65 - 74 140 (41.7%) 37 (44%) 
75 - 84 112 (33.3%) 22 (26.2%) 
≥ 85 43 (12.8%) 13 (15.5%) 
Female, no. (%) 200 (59.5%) 50 (59.5%) 1.0 
Rural location, no. (%)2 56 (16.7%) 14 (16.7%) 1.0 
Socioeconomic status, no. (%)3 
Quintile 1 72 (21.4%) 18 (21.4%) 1.0 
Quintile 2 56 (16.7%) 14 (16.7%) 1.0 
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Quintile 3 56 (16.7%) 14 (16.7%) 1.0 
Quintile 4 72 (21.4%) 18 (21.4%) 1.0 
Quintile 5 80 (23.8%) 20 (23.8%) 1.0 
Primary care physician visits, no. (%) 
Median (IQR) 8 (5-13) 12 (7-19)  
Mean ± SD 11 ± 11.26 16 ± 14.23 <0.01 
0 16 (4.8%) ≤5 
<0.01 1 - 2 34 (10.1%) 8 (9.5%) 
3 - 4 54 (16.1%) ≤5 
5 - 6 54 (16.1%) 6 (7.1%) 
<0.01 
7 - 8 37 (11%) 9 (10.7%) 
9 - 10 38 (11.3%) 9 (10.7%) 
≥ 11 103 (30.7%) 47 (56%) 
Comorbidities, no. (%) 
John Hopkins ADG Score, no. (%) 
Median (IQR) 11 (8-14) 13.5 (11-16)  
Mean ± SD 11 ± 4.19 13 ± 3.68 <0.01 
≤ 9 122 (36.3%) 12 (14.3%) 
<0.01 
10 - 12 92 (27.4%) 23 (27.4%) 
13 - 15 62 (18.5%) 22 (26.2%) 
≥ 16 60 (17.9%) 27 (32.1%) 
Malignant hypertension ≤5 ≤5 - 
Systemic lupus erythematosus ≤5 ≤5 - 
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1no.: Number, IQR: interquartile range, SD: Standardized difference, NSAIDs: non-steroidal anti-inflammatory drugs, 
ACE: angiotensin-converting enzyme, HIV: Human immunodeficiency virus 
2Rural residence is defined as population < 10,000 
3Quntiles are ranked from lowest to highest (i.e. Quintile 1 = lowest, Quintile 5 = highest) 
4P-values are calculated using generalized estimating equations 
5cells are combined or suppressed to avoid reporting numbers ≤5 
 
 
 
 
Cancer 32 (9.5%) 12 (14.3%) <0.01 
Renal transplant ≤5 ≤5 - 
Osteoarthritis 11 (3.3%) ≤5 <0.01 
Rheumatoid arthritis 18 (5.4%) 9 (10.7%) <0.01 
HIV1 ≤5 ≤5 1.0 
Sepsis Suppressed5 ≤5 1.0 
 
 
Medications, no. (%) 
Quinine ≤5 ≤5 - 
Quetiapine ≤5 ≤5 - 
Tacrolimus ≤5 ≤5 - 
Sirolimus ≤5 ≤5 - 
Cyclosporine ≤5 ≤5 - 
Clopidogrel ≤5 ≤5 - 
Ticlopidine ≤5 ≤5 - 
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Appendix G: The association between NSAID use and thrombotic microangiopathy, 
with ACE inhibitors as a reference group. Odds ratios derived from a conditional logistic 
regression model.  
 
 
Cases of TMA 
n=84 
Controls 
n=336 
Odds Ratio (95% confidence interval) 
Unadjusted Adjusted1 
ACE inhibitors2 66 (79%) 253 (75%) 1.0 (referent) 1.0 (referent) 
NSAIDs2 18 (21%) 83 (25%) 0.82 (0.45-1.49) 0.72 (0.38-1.37) 
1Adjusted analysis included the following variables: cancer, osteoarthritis, rheumatoid arthritis, John Hopkin’s ADG 
score and primary care physician visits  
2NSAIDs: Non-steroidal anti-inflammatory drugs, ACE: angiotensin-converting enzyme 
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